Alumis reports positive outcomes from Phase I trial of TYK2 inhibitor
For both the SAD and MAD portions of the trial, pharmacodynamic markers, including pSTAT levels, were measured.
Therapy Area
New screening recommendations for critical congenital heart defects
Immunocore doses first subject in gastrointestinal cancer therapy trial
HighField gains Chinese regulatory clearance to begin solid tumour therapy trial
Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial
MindMed doses first subject in trial of tablets for generalised anxiety disorder
Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial
GSK’s lung cancer therapy gains EMA PRIME designation
